Seng Chan You, Seung In Seo, Thomas Falconer, Chen Yanover, Talita Duarte-Salles, Sarah Seager, Jose D Posada, Nigam H Shah, Phung-Anh Nguyen, Yeesuk Kim, Jason C Hsu, Mui Van Zandt, Min-Huei Hsu, Hang Lak Lee, Heejoo Ko, Woon Geon Shin, Nicole Pratt, Rae Woong Park, Christin G Reich, Marc A Suchard, George Hripcsak, Chan Hyuk Park, Daniel Prieto-Alhambra
IMPORTANCE: Ranitidine, the most widely used histamine-2 receptor antagonist (H2RA), was withdrawn because of N-nitrosodimethylamine impurity in 2020. Given the worldwide exposure to this drug, the potential risk of cancer development associated with the intake of known carcinogens is an important epidemiological concern. OBJECTIVE: To examine the comparative risk of cancer associated with the use of ranitidine vs other H2RAs. DESIGN, SETTING, AND PARTICIPANTS: This new-user active comparator international network cohort study was conducted using 3 health claims and 9 electronic health record databases from the US, the United Kingdom, Germany, Spain, France, South Korea, and Taiwan...
September 5, 2023: JAMA Network Open